Elanco Animal Health (NYSE:ELAN) Releases FY25 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.80-$0.86 for the period, compared to the consensus estimate of $0.89. The company issued revenue guidance of $4.445-$4.510 billion, compared to the consensus revenue estimate of $4.52 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Elanco Animal Health Price Performance

Shares of ELAN stock traded up $0.64 during mid-day trading on Wednesday, hitting $11.34. 653,934 shares of the stock were exchanged, compared to its average volume of 4,788,184. The firm has a fifty day moving average of $11.75 and a 200 day moving average of $13.07. Elanco Animal Health has a 52-week low of $10.20 and a 52-week high of $18.80. The company has a market cap of $5.61 billion, a PE ratio of 28.34, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm earned $0.08 earnings per share. The business’s revenue was down 1.4% on a year-over-year basis. Research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ELAN. UBS Group started coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price target on the stock. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Leerink Partners started coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Hold” and an average target price of $15.86.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.